Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002059 · ClinicalTrials.gov registry record · NA
A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers
A NA study, sponsored by Newport Pharmaceuticals International.
- Completed
- Registry status
- NA
- Development phase
NCT00002059: Completed NA study, sponsored by Newport Pharmaceuticals International.
NCT00002059 is a NA study that has completed, run by Newport Pharmaceuticals International. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002059, a NA study, has completed, sponsored by Newport Pharmaceuticals International.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The objective of this double-blind placebo-controlled study is to evaluate the effect of Isoprinosine in a group of homogenous male volunteers who present with immunologic defects relative to: * Comparison of total helper and suppressor T-cell number between the groups. * Comparison of the phytohemagglutinins (PHA) and concanavalin A lymphoproliferative response and natural killer (NK) cell activity between the groups. * Determination of the clinical course of the volunteers after discontinuance of Isoprinosine.
Interventions
- DRUG Inosine pranobex
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002059 record still lists
NCT00002059 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Inosine pranobex is the first listed.
NCT00002059 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002059 about?
NCT00002059 is a clinical study titled "A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers". The objective of this double-blind placebo-controlled study is to evaluate the effect of Isoprinosine in a group of homogenous male volunteers who present with immunologic defects relative to: * Comparison of total helper and suppressor T-cell number between the groups. * Comparison of the phytohem...
What is the current status of trial NCT00002059?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002059?
The interventions under investigation include: Inosine pranobex (DRUG).
Who is sponsoring clinical trial NCT00002059?
This trial is sponsored by Newport Pharmaceuticals International, which has 6 total clinical trials registered on ClinicalTrials.gov.